GLUE
GLUE clinical trials: Monte Rosa Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Monte Rosa Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
GLUE on the catalyst calendar · GLUE registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Oct 2027Sponsor estimate | NCT07745361Study of Oral MRT-2359 With Apalutamide in Prostate CancerMonte Rosa Therapeutics, Inc · Castration-Resistant Prostate Cancer (CRPC) | GLUELead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Dec 2026Sponsor estimate | NCT05546268Study of Oral MRT-2359 in Selected Cancer PatientsMonte Rosa Therapeutics, Inc · NSCLC | GLUELead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jul 2026Sponsor estimate | NCT07119125A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPMonte Rosa Therapeutics, Inc · Healthy Volunteers | GLUELead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Apr 10, 2025Actual | NCT06597799First-in-human Study of MRT-6160 in Healthy SubjectsMonte Rosa Therapeutics, Inc · Healthy Volunteers | GLUELead | Phase 1 | Completed | Locked | Locked | Locked |
- Primary completion Oct 2027Sponsor estimatePhase 2NCT07745361Study of Oral MRT-2359 With Apalutamide in Prostate CancerMonte Rosa Therapeutics, Inc · Castration-Resistant Prostate Cancer (CRPC)RecruitingGLUELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05546268Study of Oral MRT-2359 in Selected Cancer PatientsMonte Rosa Therapeutics, Inc · NSCLCActive, not recruitingGLUELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2026Sponsor estimatePhase 1NCT07119125A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPMonte Rosa Therapeutics, Inc · Healthy VolunteersActive, not recruitingGLUELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2025ActualPhase 1NCT06597799First-in-human Study of MRT-6160 in Healthy SubjectsMonte Rosa Therapeutics, Inc · Healthy VolunteersCompletedGLUELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner